During the last three months, 15 analysts shared their evaluations of Veeva Systems VEEV, revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 7 | 5 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 5 | 4 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts have recently evaluated Veeva Systems and provided 12-month price targets. The average target is $239.27, accompanied by a high estimate of $286.00 and a low estimate of $192.00. Witnessing a positive shift, the current average has risen by 6.14% from the previous average price target of $225.43.
Diving into Analyst Ratings: An In-Depth Exploration
In examining recent analyst actions, we gain insights into how financial experts perceive Veeva Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joe Vruwink | Baird | Lowers | Outperform | $245.00 | $251.00 |
| Andrew DeGasperi | Exane BNP Paribas | Announces | Outperform | $286.00 | - |
| Jack Wallace | Guggenheim | Raises | Buy | $249.00 | $233.00 |
| Anne Samuel | JP Morgan | Raises | Neutral | $208.00 | $203.00 |
| Jailendra Singh | Truist Securities | Raises | Hold | $207.00 | $197.00 |
| Charles Rhyee | TD Cowen | Raises | Hold | $192.00 | $180.00 |
| Tyler Radke | Citigroup | Raises | Buy | $281.00 | $273.00 |
| Brent Bracelin | Piper Sandler | Raises | Overweight | $230.00 | $225.00 |
| Rishi Jaluria | RBC Capital | Maintains | Outperform | $250.00 | $250.00 |
| Brian Peterson | Raymond James | Raises | Outperform | $235.00 | $230.00 |
| Saket Kalia | Barclays | Raises | Overweight | $240.00 | $220.00 |
| Brad Sills | B of A Securities | Raises | Neutral | $240.00 | $204.00 |
| Joe Vruwink | Baird | Raises | Outperform | $251.00 | $245.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $260.00 | $260.00 |
| Karl Keirstead | UBS | Raises | Neutral | $215.00 | $185.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veeva Systems. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Veeva Systems compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Veeva Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Veeva Systems's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Veeva Systems analyst ratings.
Get to Know Veeva Systems Better
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Understanding the Numbers: Veeva Systems's Finances
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Veeva Systems's remarkable performance in 3 months is evident. As of 31 July, 2024, the company achieved an impressive revenue growth rate of 14.56%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Veeva Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 25.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Veeva Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Veeva Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.73% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Veeva Systems's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
Understanding the Relevance of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
